medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2013, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2013; 29 (4)

Evaluation of induction and consolidation classic treatment in de Novo acute non-lymphoblastic leukemia

Cabrera-Payne Y, Núñez-Quintana A, Carnot-Uria J, Muñío-Perurena J, Hernández-Cruz C, Rodríguez-Fraga Y

Language: Spanish
References: 27
Page:
PDF size: 259.15 Kb.


ABSTRACT

Introduction: validation of cytogenetic and molecular abnormalities present at diagnosis is the most important prognostic factors of acute non-lymphoblastic leukemia. This has allowed us to establish the individual risk, stratify the patients and individualize their treatment.
Objective: to describe the clinical behavior and outcome of patients with acute de novo non-lymphoblastic non-promyelocytic leukemia, receiving induction and classic consolidation therapy at the Department of Hematology of the Clinical Surgical Hospital "Hermanos Ameijeiras".
Methods: a descriptive, prospective longitudinal study was carried out with 23 patients admitted between May 2008 and January 2011. Patients were stratified into: favorable, intermediate, poor risk groups, according to biological, molecular and cytogenetics clinical prognostic factors.
Results: 60.9 % of patients had leukocyte counts less than 25 x 109/L, 47.8 % had myelomonocytic variant, 21.7 % had normal karyotype and 10% had translocation (8; 21). Mutations of the genes FLT3 and NPM1 were present in 2 and 3 patients respectively. 84 % of patients undergoing induction therapy achieved complete remission, predominantly the ones in the favorable risk group with no significant differences. In the favorable molecular risk group, the number of complete remissions was significantly higher (85.7 %) (p=0.05). The group of favorable risk patients remaining in complete remission with the consolidation treatment had 54.5 %, although it was not significant.
Conclusions: the disease free survival was greater whereas overall survival rate was similar to the data reported in the international literature. Both were higher within the favorable risk group but without no significant difference, what is considered an important achievement of Cuban Healthcare System.


REFERENCES

  1. Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, et al. End points to establish the efficacy of new agents in the treatment of acute leukaemia. Blood 2007 Mar;109 (5):1810-6.

  2. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008 May;22(5):915-31.

  3. Kiyoi H, Naoe T Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol. 2006 May;83(4):301-8.

  4. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007 Jan 15;109(2):431-48.

  5. Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004 Oct 15;104(8):2467-74.

  6. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther. 2009;31 Pt 2:2349-70.

  7. Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010 Nov 1;116(21):5012-21.

  8. VisaniG, Olivieri A, Malagola M, Brunori M, Piccaluga PP, Capelli D et al. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine. Leuk Lymphoma. 2006 Jun;47(6):1091-102.

  9. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control. 2008 May; 19(4):379-90.

  10. Grimwade D. Impact of cytogenetics on clinical outcome in AML. In: Karp JE, ed. Acute Myelogenous Leukemia. Totowa, New Jersey: Humana Press; 2007:177-192.

  11. Lichtman M, Liesveld JL. Leucemia mielogena aguda. En: Beutler E, Lichtman MA, Coller BS, editors. Hematología Williams, 6a Ed. Madrid: Marban Libros, S.L; 2005: 1047-83.

  12. Lichtman M, Liesveld JL. Acute Myelogenous Leukemia. In: Kaushansky K, Beutler E, Seligsohn U, Lichtman M, Kipps T, editors. Williams Hematology, 8th Ed. New York: McGraw-Hill Companies; 2010.

  13. Rodríguez G, Escudero A. Indicaciones actuales del trasplante alogénico en Leucemia Aguda Mieloblástica. Cuadernos de Hematología1ra ed; 2008.

  14. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008 May 1;358(18):1909-18.

  15. Scholl C, Gilliland DG, Fröhling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol. 2008 Aug;35(4):336-45..

  16. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010 Jun 1;28(16):2739-47. Epub 2010 May 3.

  17. Haferlach C, Mecucci C, Schnittger S, KohLANLnn A, Mancini M, Cuneo A, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood. 2009 Oct ;114(14):3024-32. Epub 2009 May 8.

  18. Zhu X, Ma Y, Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol, 2010 Apr;3:17 19. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML(AMLCG) 1992 Trial.. Blood 2003 Jan 1;101(1):64-70. Epub 2002 Jun 28.

  19. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML(AMLCG) 1992 Trial.. Blood 2003 Jan 1;101(1):64-70. Epub 2002 Jun 28.

  20. Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010 Nov 1;116(21):5012-21.

  21. Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003 Aug;17(8):1521-8.

  22. Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients. Leukemia 2001 Jun;15(6):903-9.

  23. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009;385–95.

  24. Estey E, Kantarjian H. Therapy for acute myeloid leukemia. In: Hoffman: Hematology: Basic Principles and Practice, 4th ed. Churchill Livingstone, An Imprint of Elsevier; 2005.

  25. Tsimberidou AM, Estey E. Induction mortality risk in adult acute myeloid leukemia. Leuk Lymphoma. 2006 Jul;47(7):1199-200.

  26. Jagarlamudi R, Kumar L, Kochupillai V, Kapil A, Banerjee U, Thulkar S. Infections in acute leukemia: an analysis of 240 febrile episodes. Med Oncol. 2000 May;17(2):111-6.

  27. Hernández C, Pérez D, Carnot J, Castro R, Muñio J, Martinez C et al. Tratamiento con quimioterapia de la Leucemia mieloide aguda en Hospital Hermanos Ameijeiras. Experiencia de 20 años de trabajo. Rev Cubana Med. 2006; 45(1): 1-9.




2020     |     www.medigraphic.com